



# NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

---

**Date:** September 17, 2008

**To:** NCCTG Primary Clinical Research Associates

**From:** Janis Wobschall  
Protocol Development Coordinator

**Re:** N027D, A Phase I Study of CCI-779 and Temozolomide in Combination with Radiation Therapy in Glioblastoma Multiforme

## **REMINDER**

There are 2 arms to this study. In Arm A patients will receive RT/TMZ/CCI-779 followed by adjuvant TMZ. Patients will have several research blood draws for evaluating immune cell function. In parallel, Arm B will treat patients with standard RT/TMZ followed by TMZ and they will have the same research blood draws as Arm A. The purpose of this arm is to evaluate the extent of immune suppression associated with TMZ therapy alone and compare this to those patient receiving CCI-779 + TMZ. Thus, for your patients who are not interested in a novel therapy or if all trials are closed, please consider enrolling patients on Arm B of N027D.